Merit Medical acquires Biolife for $120M in cash; adds StatSeal/WoundSeal hemostasis products

MERIT MEDICAL SYSTEMS INC

Purchase price $120M cash; Biolife becomes wholly-owned subsidiary of Merit.
Biolife's revenue projected at ~$18M annualized starting FY 2026 with mid-teens growth.
StatSeal/WoundSeal products address ~$350M global hemostasis market.
Merit reaffirms FY 2025 guidance; acquisition slightly dilutive to 2025 non-GAAP profitability.

item 1.01item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.